ERC-BELGIUM S.A.
Epitopoietic Research Corporation (ERC-Belgium SA) is a clinical stage emerging Biopharmaceutical Company developing a safe, highly effective approach for the treatment of cancer, particularly cancers of the brain. ERC has built a network of leading neuro-oncologists in several countries in the world, among others in the US and Europe to propel its immunotherapies through clinical development and to market. ERC’s regimen of therapeutic vaccines has shown early promise in patients suffering from recurrent Glioblastoma multiforme (GBM), the deadliest of brain cancers.
ERC-BELGIUM S.A.
Industry:
Biotechnology
Address:
Gembloux, Namur, Belgium
Country:
Belgium
Website Url:
http://www.erc-immunotherapy.com
Status:
Active
Contact:
+32 81 72 86 10
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Nginx Microsoft Exchange Online Office 365 Mail
Similar Organizations
NovaRx
NovaRx Corporation is a clinical-stage biopharmaceutical company.
Official Site Inspections
http://www.erc-immunotherapy.com
- Host name: 206.81.12.176
- IP address: 206.81.12.176
- Location: North Bergen United States
- Latitude: 40.793
- Longitude: -74.0247
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07047
More informations about "ERC-Belgium S.A."
About | ERC - erc-immunotherapy.com
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
Epitopoietic Research Corporation - Wikipedia
Epitopoietic Research Corporation (ERC) is a Belgian Pharmaceutical company that is specialized in the development of ERC1671 (Gliovac, Sitooiganap (EU)), a treatment for Glioblastoma multiforme, which is the most aggressive form of brain cancer. In 2019 ERC provided treatment under the US Federal Right-to-try law. See details»
Executive board | ERC
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
Executive Management | ERC
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
Investors | ERC - erc-immunotherapy.com
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with Glioblastoma multiforme …See details»
Milestone achievements | ERC
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
ERC Immunotherapy - Company Profile - Tracxn
Nov 27, 2024 ERC Immunotherapy (Epitopoietic Research Corporation) is a Belgian, clinical-stage biopharma developing Allogenic-autologous immunotherapy vaccine for Glioblastoma …See details»
ERC - euroquity.com
About your organization ERC has developed a unique advanced cancer cell based immunotherapy invented by Pr. Apostolos Stathopoulos for the treatment of patients suffering …See details»
ERC-Belgium S.A. - Crunchbase Company Profile & Funding
ERC has built a network of leading neuro-oncologists in several countries in the world, among others in the US and Europe to propel its immunotherapies through clinical development and …See details»
Contact | ERC - erc-immunotherapy.com
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
Epitopoietic Research Corporation - Facebook
Epitopoietic Research Corporation. 110 likes. ERC-ImmunotherapySee details»
ERC Belgium - Waw magazine
Le traitement d’ERC Belgium semble donc surpasser tout autre traitement médical standard actuel. A la différence de ses concurrents, le Gliovac garde une efficacité maximale quelles …See details»
News | ERC
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
Goethe-Universität — ERC Advanced Grant for cutting-edge …
The €2.5 million ERC Advanced Grant enables him to build on his successful research into the molecular architecture and mechanisms of the cellular immune response. ... This property of T …See details»
ERC Right To Try Policy 15JULY2019 - erc-immunotherapy.com
5.2.1.ERC by email at [email protected] 5.3. Submissions of the Right-to-Try request form shall be sent to the email address noted in the form, for review and …See details»
ERC Launches Development Program for Novel Cell-Based
Apr 9, 2020 ERC is now applying its world leading immunotherapy technology to infectious diseases such as SARS-Cov-2, Ebola and other virus without any efficient treatment or …See details»
Immunotherapy for endocrine tumours: a clinician's perspective
Feb 12, 2024 Immunotherapy has revolutionised the treatment of oncological patients, but its application in various endocrine tumours is rather limited and is mainly used when …See details»
ERC Synergy Grant 2023 for Immunotherapy of liver metastases
Oct 26, 2023 ERC Synergy Grants for Groundbreaking Research. The European Research Council (ERC) is the primary European funding organization for pioneering research. It …See details»
Gliovac/ERC1671 | ERC - erc-immunotherapy.com
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»